Vtesse, Inc. is a rare disease company dedicated to developing drugs for patients suffering from diseases that are underserved. The first spin-out company from Cydan Development, Inc., Vtesse is working collaboratively with the NIH to advance clinical study of VTS-270 for NPC, and to conduct pre-clinical discovery and development of other novel drugs for NPC and other LSDs.
Market
Rare diseases
Location
Gaithersburg,
MD,
USA
Coinvestors
Alexandria Real Estate Equities, Bay City Capital, Lundbeckfond Ventures, Pfizer Strategic Investments